ESTRO 2024 - Abstract Book

S5708

RTT - Patient experience and quality of life

ESTRO 2024

Pia Krause Møller 1,2,3 , Mette van Overeem Felter 4 , Uffe Bernchou 1,2 , Mirjana Josipovic 5,6 , Susanne Nørring Bekke 4 , Eva Serup--Hansen 4 , Parag J. Parikh 7 , Joshua P. Kim 7 , Poul Geertsen 4 , Claus P. Behrens 4,8 , Ivan R Vogelius 5,6 , Mette Pøhl 5 , Gitte Fredberg Persson 4,6 , Tine Schytte 1,2 1 Odense University Hospital, Department of Oncology, Odense, Denmark. 2 University of Southern Denmark, Department of Clinical Research, Odense, Denmark. 3 Odense University Hospital, OPEN, Open Patient data Explorative Network, Odense, Denmark. 4 Copenhagen University Hospital - Herlev and Gentofte, Department of Oncology, Herlev, Denmark. 5 Copenhagen University Hospital - Rigshospitalet, Department of Oncology, Copenhagen, Denmark. 6 University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark. 7 Henry Ford Hospital, Department of Oncology, Detroit, USA. 8 , Technical University of Denmark, Department of Health Technology, Roskilde, Denmark

Purpose/Objective:

Online MR-guided stereotactic ablative radiotherapy (MRgSABR) presents a novel treatment option and has enabled irradiation of metastases in high-risk anatomical locations. The SOFT multicenter phase II trial included patients with infradiafragmatic oligometastases for MRgSABR (clinicaltrials.gov ID NCT04407897). There is limited knowledge about patient-reported adverse events (AEs) and health-related quality of life (HRQoL) over time for patients treated with SABR 1. As previous studies have shown incongruences between clinician-reported and patient-reported outcomes (PROs), the purpose of this study was to investigate changes in patient reported symptoms in the six months following MRgSABR as well as HRQoL in the one-year follow-up period. These are the initial analyses.

Material/Methods:

The study enrolled patients from four RT centres in two countries. Depending on the target site and doses to organs at risk, 3-8 radiotherapy (RT) fractions were prescribed. Patients received a link for the ePRO system (REDCap). At five time points (end of RT, week 2, 6, 12 and 24), patients from the trial reported eight symptomatic AEs from the Patient-Reported Outcomes Version of the Common Terminology Criteria (PRO-CTCAE) item library (Table 2) and HRQoL using the EuroQol Group EQ-5D-5L questionnaire until week 52. For each event, the mean EQ-5D index value and patient's self-rated health on a vertical visual analogue scale (the EQ-VAS score) were analysed. Descriptive analyses were conducted of the maximum symptomatic PRO-CTCAE scores reported after MRgSABR using the observed maximum score if higher than the baseline score, otherwise set to the value 02.

Results:

The study enrolled 121 patients, with six undergoing a second enrollment and 24% having more than one target (Table 1). The median age was 69, the majority had oligometastatic recurrence (59%) or progressive disease (32%) (Table 1). Overall, HRQoL was stable throughout the one-year follow-up after SABR, with the mean EQ-5D index value returning to baseline level week 52 (mean 0.827 (SD 0.15)) after a slight decline in week 24 (mean 0.813 (SD 0.17)) (Table 2). As Table 3 displays, fatigue (53%) was the most common symptom reported by the patients post MRgSABR. For the majority the worst severity of fatigue was mild but for 16%, moderate to very severe. The frequency of nausea and diarrhoea increased post-baseline to 30% and 33%, respectively. Both symptoms were most frequent at the end of MRgSABR occurring rarely or occasionally (86-88%) with a mild to moderate severity.